Skip to content
Company Terminals IPO Intel Calculators Gold Desk Research Services Roadmap Pricing Get started →
The $13 Billion Machine: Inside the Macro-Economics of the 2026 FIFA World CupAlibaba share price is up 16% today. what next for Baba stock?IPO Allotment status check online by PAN number 2025UnitedHealth (UNH Stock): You should stay away from itQ4 results live updates: Adani Group companies in focusThe $13 Billion Machine: Inside the Macro-Economics of the 2026 FIFA World CupAlibaba share price is up 16% today. what next for Baba stock?IPO Allotment status check online by PAN number 2025UnitedHealth (UNH Stock): You should stay away from itQ4 results live updates: Adani Group companies in focus

Molbio Diagnostics

MOLBIO · Hospital & Healthcare Services · INE869T01028

Analyst mean 0.00 · 0 analysts · 0% bullish
₹1,264.00
Close 2026-09-22 · Extreme risk
Price
₹1,264.00
Mkt cap
₹14,569 cr
P/E (TTM)
82.5xexcl. exceptional items
P/B
11.75x
Book value
₹101.4
D/E
0.38
Consolidatedstandalone figures are read separately and never mixed into these tables

What's newsince the last filing we processed

Earnings call Sep 2026 Open
Announcement 9 Sep - Molbio Diagnostics’ CIN changed to L33125GA2000PLC002909; MCA status updated to listed after NSE/BSE listing. Open

Read from the offer document

This company listed within the last twelve months, so its prospectus is still the primary source. The figures below were extracted from the DRHP and RHP before listing and scored then, and they are shown here as they stand in the IPO record rather than restated.

63/100 88% coverage
₹807 Mainboard
₹940 cr
+21.4%

What the score is made of

Score components
Issue structure70
Financial quality70
Valuation vs peers55
Underwriter quality75
Governance forensics52

Flagged in the offer document

Each flag is a fact read in the filing, shown with the context that makes it meaningful.

  • Audit Trail (Edit Log) Gaps and Backup Failures flagged
  • Intermediary Fund Routing flagged
  • Discrepancies in Bank Stock and Debt Statements flagged
  • Multiple Prior Employee and Vendor Frauds flagged
  • Government and Aid Agency Revenue Concentration noted
  • Material Uncertainty Over Subsidiary Financial Viability noted

What the issue was raised for

Stated objects, as worded in the offer document. Deployment against them is tracked separately.

  • Source: RHP p. 37, 128, 129 · Purpose: Funding capital expenditure towards the setting up of infrastructure for a research and development facility and Center of Excellence which will be operated by our wholly-owned Subsidiary, Bigtec, and connected office space for our Company, Subsidiaries and Associate · Amount cr: 105.535
  • Source: RHP p. 37, 129, 134 · Purpose: Funding capital expenditure towards the purchase of certain plant, machinery and other equipment for Goa Unit I, Goa Unit II and Visakhapatnam Unit · Amount cr: 72.281
  • Source: RHP p. 129 · Purpose: General corporate purposes

What the company said

Claims made in the offer document, to be read against what the company has reported since.

  • We have a scalable business model with strong entry barriers and a high proportion of recurring revenues driven by our Truenat molecular diagnostic platform.
  • The company possesses strong entry barriers based on R&D focus and unique regulatory/WHO clearances.

Lock-in

  • Period: three years · Source: RHP p. 112 · Category: Minimum Promoters' Contribution
  • Period: one year · Source: RHP p. 112, 113 · Category: Promoters' shareholding in excess of Minimum Promoters' Contribution
  • Period: six months · Source: RHP p. 113 · Category: Entire pre-Offer equity share capital
  • Period: 90 days · Source: RHP p. 114 · Category: Anchor Investors (50%)
  • Period: 30 days · Source: RHP p. 114 · Category: Anchor Investors (50%)

The business

What it does

Deep

Incorporated in 2000, Molbio Diagnostics Limited is a pioneer in the point-of-care (POC) molecular diagnostics space in India. Its flagship product, the 'Truenat' platform, is a battery-operated, portable real-time PCR system that performs automated sample preparation and analyzer functions, delivering results in under an hour even in resource-limited settings. The company has commercialized molecular testing for 30 diseases with 43 assays as of March 31, 2026, including tuberculosis, COVID-19, Hepatitis B/C, HIV, and HPV. Molbio relies heavily on public health programs, deriving 84.56% of its finished goods revenue in FY26 from Indian central/state governments and international aid agencies. The company's top ten customers, including the Central Medical Services Society, generated 83.26% of FY26 finished goods revenue. Molbio operates six manufacturing facilities in India (in Goa, Bengaluru, and Visakhapatnam) and is highly research-focused, conducting R&D through its wholly-owned subsidiary, Bigtec Private Limited. It also offers digital pathology, radiology, and breast health screening through subsidiaries like Prognosys and OptraScan. With institutional backing from Temasek and Motilal Oswal, the company has commercialized its products globally, exporting to more than 90 countries.

Moat

Molbio has created a strong entry barrier and oligopolistic positioning with its 'Truenat' platform, which underwent 13 years of R&D to obtain ICMR certification. Its Truenat test chip for diagnosing TB is the only one developed by an Indian company (and one of only two globally) endorsed by the WHO for initial diagnosis and rifampicin resistance detection. The platform operates on a razor-and-blade model, generating high-margin, recurring revenues from proprietary disease-specific test kits that must be used with the device.

Short

Molbio Diagnostics Limited is an innovative point-of-care (POC) diagnostics company that designs, develops, and manufactures portable, real-time PCR platforms and diagnostic test kits. The company generates recurring revenue primarily through the sale of its 'Truenat' test kits and devices to public healthcare programs, private laboratories, and hospitals.

Source: RHP p. 142, 215, 219

Revenue segments

Where the revenue came from, as the document splits it.

Pct
Revenue from sale of test kits71.6%
Revenue from sale of devices14.1%
Others (including subsidiary revenues and other operating revenues)14.4%
The numbers behind it
NamePctSource
Revenue from sale of test kits71.58RHP p. 144, 218
Revenue from sale of devices14.06RHP p. 144, 218
Others (including subsidiary revenues and other operating revenues)14.36RHP p. 218
The industry

Summary

According to the 1Lattice Report, the global point-of-care testing (POCT) market is experiencing rapid expansion, driven by the increasing relevance of near-patient diagnostics, which offer faster turnaround times, lower capital costs, and ease of use in resource-limited or decentralized settings. Electrification and battery operation are crucial for penetration in emerging economies. Molecular diagnostics represents a highly competitive yet high-barrier space characterized by intensive R&D, stringent regulatory clearances (such as ICMR and WHO), and oligopolistic structures. Key growth areas include infectious disease screening (such as TB and COVID-19) and non-communicable diseases. Established players with strong technological IP, razor-and-blade recurring revenue profiles, and validated manufacturing capabilities are well-positioned to capitalize on this shift from centralized laboratory testing.

Growth rate: 17.9% CAGR between 2025 and 2030

Market size: USD 29.3 billion (equivalent to ₹ 2,588.6 billion) (Global POCT Market)

Sector slug: point-of-care-diagnostics

Source: RHP p. 175, 215, 219

Peers named in the document

The comparable set the company chose, which is itself a disclosure.

NameMarginPbPeRoeSource
Poly Medicure Limited52.6110.37RHP p. 142
Dr. Lal Pathlabs Limited62.220.78RHP p. 142
Metropolis Healthcare Limited63.7212.56RHP p. 142
Vijaya Diagnostics Centre Limited81.0218.07RHP p. 142

The numbers as filed

Financials

As presented in the offer document. Post-listing figures are in the statements above.

Revenue crPat cr
83783.5
FY24
1,02139
FY25
1,446164
FY26
The numbers behind it
PeriodRelated party revenue crPat crEbitda crPat marginRevenue crPat margin derivedCff cr
FY26164.14328.24311.35%1445.687yes276.066
FY25138.579256.63913.58%1020.418yes-26.147
FY2483.542185.0939.99%836.561yes-31.553
The questions worth asking

Written before listing, answered from the document itself.

Where is the money going?

The Net Proceeds from the ₹200.00 crore Fresh Issue are being deployed towards capital expenditure. Specifically, ₹105.54 crore is allocated for setting up research and development infrastructure and a Center of Excellence for wholly-owned subsidiary Bigtec, and ₹72.28 crore is earmarked for purchasing plant, machinery, and automation equipment for manufacturing units in Goa and Visakhapatnam.

RHP p. 37, 128-129

How concentrated is the customer base?

The customer base is highly concentrated. The top 10 customers contributed 83.26% of finished goods sales in FY26 (compared to 83.62% in FY25 and 78.54% in FY24). Additionally, finished goods sales to central/state government healthcare programs and international aid agencies represented 84.56% of total contract sales in FY26.

RHP p. 28, 368

Is it profitable and growing?

Yes. Revenue from operations increased from ₹836.56 crore in FY24 to ₹1,020.42 crore in FY25, and scaled to ₹1,445.69 crore in FY26. Consolidated net profit (PAT) was ₹83.54 crore in FY24, ₹138.58 crore in FY25, and ₹164.14 crore in FY26, maintaining an EBITDA margin of 22.56% in FY26.

RHP p. 79, 316, 371

What sits in the footnotes / contingent liabilities?

As of March 31, 2026, contingent liabilities total ₹1,687.42 million (comprising bank guarantees of ₹900.98 million, direct tax disputes of ₹461.48 million, indirect tax disputes of ₹322.37 million, and other claims of ₹2.59 million). Footnotes also disclose outstanding Income Tax department demands of ₹234.17 million following a survey under Section 133A, along with recurring statutory auditor exceptions regarding unenabled database-level audit trails and missing daily local server backups.

RHP p. 62, 84, 175, 419, 420, 425, 426, 428, 782, 803

Valuation at issue

What the issue priced at, on the figures in the document.

RHP p. 66, 142

The offer, ownership and risks

Pre-IPO investors
DateNameSharesPrice per shareCategorySource
2021-05-31India Business Excellence Fund III1931387248.7financial investorRHP p. 103
2021-05-31India Business Excellence Fund III314947248.7financial investorRHP p. 103
2022-09-23V Sciences Investments Pte. Ltd.734054495.91financial investorRHP p. 103
2024-09-03Shankar Gopalkrishnan15350651.46financial investorRHP p. 103
Management

Ceo: Sriram Natarajan

Litigation

Outstanding tax claims against the Company total 11 cases involving an aggregate disputed amount of ₹507.81 million (comprising ₹235.02 million in direct taxes and ₹272.79 million in indirect taxes). In addition, Promoter Sriram Natarajan has 1 pending direct tax dispute involving ₹46.03 million. Pending criminal proceedings filed by the Company and its subsidiaries total ₹188.89 million.

Skin in game

Promoters collectively hold 52,597,450 Equity Shares, which represents 46.65% of the pre-Offer paid-up equity share capital of the Company on a fully diluted basis. None of the promoter shares are pledged or otherwise encumbered as of the RHP date.

Auditor rpt flags

Statutory auditors included emphasis of matter paragraphs regarding a ₹199.00 million EMD fraud in subsidiary Prognosys Medical Systems and audit modifications/qualifications regarding unenabled database-level audit trails, disabled edit logs, and missing daily offsite server backups of electronic books of account. Significant related party transactions include a ₹1,233.62 million royalty expense paid to Bigtec Private Limited in FY26.

Source: RHP p. 22, 28, 36, 62, 84, 88, 101, 110, 137, 417, 419, 420, 422, 425, 426, 428, 803, 828, 836

What changed between DRHP and RHP

A change between the two filings is a disclosure in itself.

FieldRhp valueDrhp valueNoteSource
Offer for Sale (OFS) Share VolumeUp to 9,166,000 Equity SharesUp to 12,556,000 Equity SharesThe Offer for Sale size was reduced by 3,390,000 Equity Shares (representing a 27.00% reduction), while the Fresh Issue component remained unchanged at up to ₹ 2,000.00 million.DRHP p. 4, 122; RHP p. 445, 511
Financial Information PeriodRestated Consolidated Summary Statements for Fiscals 2026, 2025 and 2024Restated Consolidated Summary Statements for Fiscals 2025, 2024 and 2023The financial disclosures were rolled forward to include full Fiscal 2026 financials, dropping the oldest reporting year (Fiscal 2023).DRHP p. 16, 41; RHP p. 456, 478
Chief Financial OfficerManan Bimal KhokhaniAmol Narayan LoneThe company appointed Manan Bimal Khokhani as the new Chief Financial Officer, replacing Amol Narayan Lone, effective December 22, 2025.DRHP p. 209, 218; RHP p. 521, 639, 847
Use of Proceeds (CAPEX for R&D facility and Center of Excellence)Up to ₹ 1,055.35 millionUp to ₹ 993.68 millionThe proposed allocation from Net Proceeds for setting up the R&D facility and Center of Excellence was increased by ₹ 61.67 million.DRHP p. 145; RHP p. 471, 128
Weighted Average Cost of Acquisition (WACA) in preceding 1 Year₹ 1,090.00 per share₹ 1,042.95 per shareThe weighted average cost of acquisition of shares transacted in the 1 year preceding the prospectus increased from ₹ 1,042.95 to ₹ 1,090.00, reflecting secondary transactions executed up to October 4, 2025.DRHP p. 71; RHP p. 567
The offer and who ran it
Ownership around the issue
Promoter, pre-issue46.7%
Pledged0%
200 cr
46.65%
0%
1
18
14,526
KFin Technologies Limited
Kotak Mahindra Capital Company Limited, IIFL Capital Services Limited (formerly known as IIFL Securities Limited), Jefferies India Private Limited, Motilal Oswal Investment Advisors Limited

Price in context split-adjusted

1M
+15.1%
From high
-16.3%
worst -19%
Close 50-DMA 200-DMA own P/E band (median ±1σ)
Trading at 97.1x against its own 10-year median of 18.8x1.9σ above its usual range. This compares the company with its own history, not with other companies.

Numbered markers are corporate actions and, once the filings are read, capital and governance events. Prices are split-adjusted so the series is continuous.

Reading the Statements forensic interpretation

What the numbers mean when read together — computed from the filings, not a score.

Cash is running well behind profit this year

Operating cash is 30% of trailing profit. On its own this can be working-capital timing in a growth year — worth watching whether it persists.

Why this reading: Kept at caution, not flagged: it is a single-year gap and the multi-year cash record does not (yet) show a repeated shortfall. One soft year is not a verdict.

Full read

Operating cash ₹50 cr vs trailing profit ₹164 cr. A one-year gap below 0.5 is often growth working capital; it becomes a real concern only if it recurs.

Borrowing while holding investments

Borrowings rose 145% over two years while the company also carries ₹6 cr in investments. Why borrow at interest while parking money elsewhere is a fair question.

Why this reading: Noted with caution — worth watching, but not yet conclusive on its own. Business has ups and downs; one soft reading is not a verdict.

Full read

Borrowings moved to ₹450 cr from ₹184 cr. Simultaneous large investments can be legitimate treasury management, or a sign that reported cash is not freely available.

Borrowing is funding real capacity

Debt rose over 2 years, and most of it (96%) has turned into fixed assets and projects under construction — the borrowing is building the business.

Why this reading: A positive signal: leverage taken on is visibly becoming productive capacity, not disappearing.

Full read

New borrowing ₹266 cr largely matched by an asset build of ₹256 cr. Debt that funds capacity is a different thing from debt that funds nothing.

Generates free cash

Free cash flow is positive and consistent — the business funds itself after capex.

Why this reading: A positive signal in the numbers, shown for balance alongside the concerns.

Full read

Latest free cash flow ₹1 cr. Negative in only 1 of 3 years. A self-funding business needs less external capital and dilutes less.

Forensic modelscomputed from the filed statements

Every score below is calculated here from the reported numbers — none of it is asserted. Open the notebook at the foot of the section to see each formula with this company's figures in it.

Altman Z″

Needs current assets and current liabilities.

Piotroski F

2 / 8 1 not testable
  • Profitable this year
  • Operating cash positive
  • Return on assets improved
  • Cash exceeds profit
  • Leverage reduced
  • Liquidity improved
  • No share dilution
  • Margin improved
  • Assets working harder
What is this, and how do I read it?

Piotroski F-Score — fundamental momentum — Joseph Piotroski, University of Chicago, 2000, in a study of whether accounting signals could improve returns among cheap stocks.

Nine yes-or-no tests across profitability, leverage and operating efficiency. Each pass scores one. It asks a narrow question: is this business getting better or worse on its own terms, year over year?

Profitability (4 tests)
Positive profit, positive operating cash, improving return on assets, and cash exceeding profit. The last is the quality test — profit that outruns cash is the one to question.
Leverage and liquidity (3 tests)
Falling debt, improving current ratio, no new shares issued. Growth funded by dilution scores zero here.
Operating efficiency (2 tests)
Improving margin and improving asset turnover.

How to read it7 or more suggests improving fundamentals; 3 or fewer suggests deterioration. It measures direction, not quality — a weak company improving can score higher than a strong one holding steady.

Where it failsA single year of comparison, so one unusual year distorts it. Says nothing about valuation, competitive position or management. Piotroski designed it to rank already-cheap stocks, not to judge a company in isolation.

Beneish M

Needs trade receivables, current assets, other expenses.

Cash vs profit

0.90× 3-year cumulative

Accruals are 6.4% of assets. Free cash flow negative in 1 of 3 years.

DuPont — return on equity FY2026

Net margin11.3%× Asset turnover0.68×× Leverage1.81×= ROE14.0%
What is this, and how do I read it?

DuPont decomposition — Devised inside the DuPont Corporation in the 1920s and still the standard way to read a return on equity.

Splits return on equity into its three sources, so the same headline number can be traced to very different businesses.

Net margin
What the company keeps from each rupee of sales. High margin points to pricing power or a genuine cost advantage.
Asset turnover
Sales generated per rupee of assets. High turnover points to efficiency — a retailer earns this way, a utility never will.
Leverage (equity multiplier)
Assets divided by equity. This multiplies whatever the first two produce, in both directions.

How to read itA 20% ROE built on margin and turnover is a different proposition from a 20% ROE built on 3× leverage. The first survives a downturn; the second amplifies it.

Where it failsA single year. Negative equity makes it meaningless. Leverage is structural for lenders, so the third term carries no signal there.

Leverage & coverage FY2026

Debt / equity0.38×
Interest coverage8.00×
ROCE18.0%

Capital that builds FY2024 → FY2026

Capital deployed+88%
Revenue produced+73%
Still in CWIP₹11 cr

Capital and revenue are growing at broadly similar rates — the asset base is being used, not just added to.

The formula notebook — every number above, worked out
Cash vs profit cumulative operating cash flow ÷ cumulative net profit ₹347 cr ÷ ₹387 cr, over 3 years 0.90× Below 1.0 and persistent means profit is being recognised before the cash arrives.
Accruals (Sloan) (net profit − operating cash flow) ÷ average total assets (₹164 − ₹50) cr ÷ average assets 6.4% The share of profit that is accounting entries rather than cash. Above ~10% is where accruals start to dominate.
DuPont — return on equity net margin × asset turnover × leverage 11.3% × 0.68 × 1.81 14.0% Splits ROE into whether returns come from operations or from borrowing.
Interest coverage EBIT ÷ finance cost ₹264 cr ÷ ₹33 cr 8.00× How many times operating profit covers the interest bill.
Debt to equity borrowings ÷ net worth ₹450 cr ÷ ₹1,169 cr 0.38× Read against the sector — infrastructure carries more than software.
Capital that builds growth in fixed assets + CWIP, against growth in revenue capital +88% vs revenue +73%, FY2024 to FY2026 15pp gap Money going in far faster than revenue coming out. For an incubator this is expected — the test is whether it eventually converts.

Going deepersame statements, harder questions

Montier C-Score

Needs more balance-sheet detail (only 3 of 6 flags testable).

Return on invested capital FY2026

ROIC12.2%
Capital employed₹1,619 cr

NOPAT over equity plus debt less cash, at a notional 25% tax. Incremental ROIC is the return on money put in since then — the number that decides whether growth creates value or consumes it.

What is this, and how do I read it?

Return on invested capital, and incremental ROIC — Standard in corporate finance; the incremental form was popularised by Michael Mauboussin as the test of whether growth creates value.

ROIC measures what the business earns on all the capital it employs — equity plus debt, less cash. Incremental ROIC asks a sharper question: what has it earned on the money put in since a chosen year?

NOPAT
Operating profit after a notional tax charge, so the figure is independent of how the company is financed. We use 25%.
Invested capital
Equity plus borrowings less cash — the money actually at work.
Incremental ROIC
Change in NOPAT divided by change in invested capital. If it sits below the cost of capital, growth is destroying value however fast revenue rises.

How to read itROIC comfortably above the cost of capital — call it 11–13% in India — means growth compounds. Below it, growth consumes. Incremental below headline means recent investment is earning less than the legacy business.

Where it failsDistorted in the year of a large acquisition. Understated for companies mid-build, where capital is deployed but capacity has not yet been commissioned — an incubator will look poor until it does not.

Earnings quality ladder FY2026

Cash ÷ EBITDA0.16×
Cash ÷ profit0.30×
Free cash ÷ profit0.01×

Read downward. Cash can cover EBITDA and still not survive capex — the third rung is where a capital-hungry business shows itself.

What is this, and how do I read it?

The earnings quality ladder — Not a named model — the standard sequence an analyst walks when testing whether reported profit is real.

Three ratios read in order, each stricter than the last.

Cash ÷ EBITDA
Does operating profit arrive as cash? Below 0.8 points to working capital absorbing it.
Cash ÷ profit
Does bottom-line profit arrive as cash? Below 1.0 persistently is the classic warning.
Free cash ÷ profit
Does anything survive capex? This is where capital-hungry businesses reveal themselves — a company can pass the first two and still never generate spendable cash.

How to read itRead downward. Each rung failing where the one above passed tells you exactly where the cash is going.

Where it failsA single year of heavy capex depresses the third rung legitimately. Judge it across a cycle.

What the price implies

60.0% free cash flow growth, every year for ten years

The growth rate that makes today's market value equal the discounted cash flows, at a 11.5% discount rate and 4.0% terminal growth. Not a forecast — the arithmetic of what is already in the price. Compare it with what the business has actually delivered.

What is this, and how do I read it?

Reverse DCF — the growth already in the price — A standard inversion of discounted cash flow, used to avoid the forecasting problem entirely.

Instead of forecasting cash flows and deriving a value, it takes today's market value as given and solves for the growth rate that would justify it. The output is not a view — it is the arithmetic of what the market is currently assuming.

Discount rate
The return required for the risk taken. We use 11.5%, roughly the long-run cost of equity in India.
Terminal growth
Growth beyond the explicit ten years. We use 4%, near long-run nominal GDP.
The output
The free-cash-flow growth rate, every year for a decade, that makes the discounted total equal today's market value.

How to read itCompare it with what the business has actually delivered. A price implying 30% a year against a decade of 15% is a demanding assumption; the reverse is a modest one.

Where it failsUseless when free cash flow is negative or unusually depressed, which is common mid-capex. Highly sensitive to the discount rate — a point either way moves the answer materially.

Cost of debt FY2026

Interest ÷ average borrowings11.06%
Average borrowings₹299 cr

Against a policy rate near 6%, most sound Indian corporates borrow between 7% and 10%.

What is this, and how do I read it?

Cost of debt — Interest expense over average borrowings — the effective rate the company actually pays.

What the lenders charge, which is a market verdict on credit quality that no rating agency delay affects.

Well below the policy rate
Suggests interest is being capitalised into assets rather than expensed, or that funding comes from related parties on non-market terms.
Near the policy rate plus a normal spread
Ordinary bank funding. Nothing to explain.
Well above
Lenders are pricing risk the equity market may not yet be.

How to read itAgainst a policy rate near 6%, most sound Indian corporates borrow between 7% and 10%. Read the direction over years as much as the level.

Where it failsUnderstated where a large share of interest is capitalised into projects under construction. Not meaningful for lenders, where interest is cost of goods.

Reading the numbers on this pagetwo bases, both shown

What the filings we hold do not give

Models that need these lines are withheld rather than estimated: net worth, current assets, current liabilities, trade receivables, inventory, net block. Nothing on this page is back-solved from a figure the company did not publish.

Published screening frameworksrules applied, not opinions quoted

Each framework below is a set of stated, mechanical criteria from published work, run against this company's own filed numbers. Passing or failing a screen is not a verdict — different frameworks disagree by design, and that disagreement is itself informative.

Graham — defensive investor

2 / 4
  • Debt below net worth ₹450 cr vs ₹1,169 cr
  • Positive earnings every year 3 of 3 years
  • P/E below 15 82.5×
  • P/E × P/B below 22.5 969.3

Benjamin Graham's stated criteria for a defensive stock, applied to the filed numbers. A company failing several is not disqualified — Graham designed these to be deliberately strict.

Greenblatt — magic formula

0 / 2
  • Return on capital above 20% 16.3%
  • Earnings yield above 8% 1.2%

Two ratios only: what the business earns on its capital, and what you pay for those earnings. Designed to be ranked across a universe rather than read in isolation.

O'Neil — CAN SLIM growth tests

1 / 4
  • Annual earnings growth above 25% -77%
  • Revenue growth above 20% 42%
  • Return on equity above 17% 14.0%
  • Share count not expanding equity capital ₹11 cr

The fundamental half of William O'Neil's framework. The market and leadership components are judgement calls and are not scored here.

Quality — compounder tests

3 / 4
  • Cash conversion above 0.9× 0.90× over 3 years
  • ROCE above 15% 18.0%
  • Interest covered more than 4× 8.00×
  • Debt below half of equity 0.38×

The characteristics long-term holders commonly look for: cash-backed earnings, high returns on capital, and debt that never forces a decision.

The page in pictures

Revenue and what it leaves behind

Bars are revenue; the line is net margin. Revenue rising while the line falls is the shape worth noticing.

FY24 · 837FY24FY25 · 1,020FY25FY26 · 1,446FY26
Revenue (₹ cr)Net margin %

Where the year's cash went — FY2026

Operating cash first, then what the business spent and raised.

50Operating cash−54Investing276Financing

Quality over time

One year is a snapshot. These are the two lines that matter across a cycle.

2.31.50.7-0.1FY24FY25FY26
Cash ÷ profit (×)ROCE (÷10)

Where cash gets stuck

Rising debtor or inventory days against flat sales is the earliest visible sign of stress.

46232719358FY24FY25FY26
Debtor daysInventory daysPayable daysCash cycle
Growth & valuation workspace

Set your own assumptions and watch the numbers move. A scenario calculator — the outputs are the arithmetic of your inputs.

User-driven scenario tool. Implied value and CAGR follow only from the assumptions you set — not a FinMinutes forecast, recommendation, or target price.

Valuation & quality

One canonical set of figures — the same numbers used everywhere else on this page and on the screener.

What you payHow the price compares with earnings, book and sales.
P/E (TTM)
82.5x
trailing 12m, live feed
P/B
11.75x
How it is fundedLeverage and what is returned to shareholders.
Debt / equity
0.38
conservative
Book value / share
₹101.4

Ownership & Skin in the Game

How the register has moved over recent quarters — the direction matters more than the level.

Promoter ― 0.00
Aug '26*41.29%

Promoter held steady from 41.29% to 41.29% across these quarters.

FII ― 0.00
Aug '26*1.51%

FII held steady from 1.51% to 1.51% across these quarters.

MF ― 0.00
Aug '26*2.25%

MF held steady from 2.25% to 2.25% across these quarters.

Other ― 0.00
Aug '26*54.95%

Other held steady from 54.95% to 54.95% across these quarters.

Working capital12-year series

Where cash gets stuck. A rising inventory or debtor line against flat sales is the earliest sign of trouble in the numbers.

MeasureFY2024FY2025FY2026
Debtor days
How long customers take to pay
18697103
Inventory days
How long stock sits before it sells
338384285
Payable days
How long the company takes to pay suppliers
101203126
Cash conversion cycle
Debtor + inventory − payable days
423278261
Working capital days200128116
ROCE %
Return on capital employed
21.0%18.0%
Trends

The shape of the business over time (annual) — read the direction, not the single print.

Revenue (₹ cr)
FY2024837FY20251.0kFY20261.4k
Net profit (₹ cr)
FY202484.0FY2025139FY2026164

Annual Profit & Loss ₹ cr

LineFY2024FY2025FY2026
Revenue from operations8371,0201,446
Other income-49-49
Depreciation414564
Finance cost141833
Profit before tax130194231
Net profit (owners)84139164
EPS (₹)452.3764.3414.77

Exceptional items, total income and EBITDA are read from the filed statements.

Quarterly Financials ₹ cr

MetricJun 2025Mar 2026Jun 2026
Revenue100561408
Other Income153
Expenses116402308
Depreciation122017
Finance cost41211
Profit before tax-3113276
Net Profit-249653
EPS-10.518.065.21

Balance Sheet ₹ cr, annual

ItemFY2024FY2025FY2026
Equity Capital2211
Reserves8219661,158
Borrowings184147450
Net block289290536
CWIP22711
Investments6466
Total Assets1,2181,4612,115

Cash Flow ₹ cr

LineFY2024FY2025FY2026
Cash from operations1028750
Cash from investing-45-123-54
Cash from financing-32-26276
Free cash flow-72321
Net change in cash-67138273

Cash from operations is the number profit has to answer to. Free cash flow is what remains after the business pays for its own growth.

Disclosure & evidencewhat the filings actually show

These are coverage counts, not ratings. Each one asks a fixed set of questions of the filings and reports how many the company answered. A company that discloses nothing counts nothing here — that is a statement about the disclosure, not about the business.

Capital discipline

4 of 4 disclosed weighted 10 of 10
What was looked for
  • Profit converts to cash — 0.90× over 3 years
  • Free cash flow not persistently negative — 1 of 3 years negative
  • Capital converts into revenue — capital +88% vs revenue +73%
  • Interest comfortably covered — 8.00×

Others in Hospital & Healthcare Services

The same read, applied to the companies this one competes with.

DISCLAIMER: FinMinutes is a financial data and analytics platform, not a registered investment adviser. Everything here is for educational and informational purposes. Forensic interpretations are computed from disclosed data and are not recommendations. Do your own due diligence.
Chat on WhatsApp